|
|
|
|
Rapid, low‑cost checks can catch construct issues that limit vector manufacturing, enabling early fixes to improve titers, avoid delays, and accelerate gene therapy programs.
|
|
|
|
|
Plasmid engineering and process development boosted viral titer 12.5×, eliminating manufacturing bottlenecks and enabling an on‑time regulatory submission for the cell therapy program.
|
|
|
|
|
Choosing the right CDMO requires early internal assessment plus strong technical capability, agility, advocacy, clear communication, and long‑term alignment to meet evolving cell and gene therapy needs.
|
|
|
|
|
Silencing cargo gene expression during LVV and AAV production improves cell health, reduces impurities, and significantly increases vector yield for cytotoxic and difficult‑to‑manufacture transgenes.
|
|
|
|
|
|
|
Minaris is a specialized global CDMO, offering end-to-end development, manufacturing, and testing services with over 25 years of expertise and personalized client support.
|
|
|
